The pediatric solid organ transplant follow-up clinic is one of the most cognitively demanding environments in outpatient pediatric care, not because the patients are acutely ill — most of the time they are not — but because the management is driven almost entirely by biological processes that produce no symptoms until they have already caused irreversible damage. A child two years out from a kidney transplant who feels completely well, plays soccer after school, and has a creatinine that looks fine may have a tacrolimus trough that has drifted below the therapeutic range over the preceding three months as her liver’s CYP3A4 enzyme activity matured, producing subclinical T-cell activity against the allograft that is accumulating quietly in the renal interstitium. A child who has been stable on the same immunosuppression regimen for years may have EBV-infected B-cells proliferating in his lymph nodes in a pattern that will require reducing the very medication protecting his kidney. A child who has never had a documented rejection episode may be one missed dose away from an acute cellular rejection event that produces no warning signs in the hours before the creatinine rises.
The transplant follow-up nurse is the clinician who makes these invisible processes visible to families who have learned, quite rationally, to measure their child’s health by how the child looks and feels. The three conversations in this post occur in the outpatient transplant clinic at three Texas medical centers, with three families navigating three of the most common and most counterintuitive communication challenges in pediatric post-transplant care: why success does not mean stopping the medication, why wellness does not mean the dose is correct, and why treating the new diagnosis means changing the medication that has been protecting the organ.
Scenario 1: Mateo García-Santos — Houston, Texas
Pediatric transplant follow-up nurse Ana Herrera-Torres and the mother who cannot understand why a successful two-year kidney transplant still requires tacrolimus twice daily for the rest of his life
Mateo is twelve years old. He received a living-donor kidney transplant at age ten from his father, Alejandro García-Santos, a plumbing contractor. The donor surgery went well; the recipient course was uncomplicated. Mateo had one mild acute cellular rejection episode at six weeks post-transplant, treated with pulse steroids and a tacrolimus dose increase, with complete creatinine recovery. Since then — twenty-two months — he has had no rejection episodes, no opportunistic infections, and stable creatinine. His tacrolimus troughs have been consistently in the 6 to 8 ng per mL range. He attends seventh grade, plays recreational soccer on weekends, and by every observable measure is a healthy twelve-year-old who had a kidney problem and does not have one anymore.
His mother, Sofía Santos-Morales, works as a dental office receptionist and has been the primary coordinator of Mateo’s care since the transplant. She arrives at this routine twelve-month follow-up visit with a question she has been accumulating for months, asking her husband, her sister, and her mother for their opinion, and finally writing down: why does Mateo need to take tacrolimus for the rest of his life if the transplant was a success and he has had no problems in almost two years?
Nurse Ana Herrera-Torres has been working in the pediatric nephrology and transplant clinic at Texas Children’s for nine years. She recognizes this question as one of the most important conversations in transplant follow-up care, because the answer is non-intuitive and the stakes of misunderstanding it are very high. She sits down, asks Mateo how seventh grade is going — “Bien. Matemáticas son difíciles.” — and then turns to Sofía.
“¿Tiene una pregunta que quería hacerme?”
(Do you have a question you wanted to ask me?)
Sofía unfolds the piece of paper. “Dos años sin rechazo, el riñón funcionando perfectamente, Mateo sintiéndose bien. Siempre me habían dicho que el tacrolimus era permanente, pero quería entender el por qué. ¿El sistema inmune no aprendió que el riñón es de Mateo ahora?”
(Two years without rejection, the kidney functioning perfectly, Mateo feeling well. I had always been told that tacrolimus was permanent, but I wanted to understand the why. Did the immune system not learn that the kidney is Mateo’s now?)
Ana nods. She has heard this question many times in many forms: “¿Cuándo termina el tacrolimus?” “¿Nunca se cura completamente el trasplante?” “¿No va a poder vivir sin el medicamento algún día?” She knows the answer requires correcting a fundamental misconception about what the tacrolimus is doing, because the frame — the immune system “learning” to accept the kidney — is the wrong frame.
“La respuesta corta es no — el sistema inmune de Mateo no aprendió que el riñón es de él. Y eso no es un fracaso del trasplante ni del tratamiento. Es la biología de cómo funciona el sistema inmune con los tejidos de otra persona. Déjeme explicarle la diferencia entre lo que el tacrolimus hace y lo que muchas familias creen que hace, porque son cosas completamente distintas.”
(The short answer is no — Mateo’s immune system did not learn that the kidney is his. And that is not a failure of the transplant or the treatment. It is the biology of how the immune system works with another person’s tissue. Let me explain the difference between what tacrolimus does and what many families believe it does, because they are completely different things.)
Sofía sets down the paper. “Adelante.”
(Go ahead.)
“Las células del riñón de Alejandro — el papá de Mateo — tienen marcadores de identidad en su superficie. Se llaman HLA, por sus siglas en inglés. Son como una huella digital celular: cada persona tiene los suyos. El riñón de Alejandro tiene los HLA de Alejandro. El sistema inmune de Mateo tiene los HLA de Mateo — que son parecidos pero no idénticos a los de su papá, porque heredó la mitad de cada progenitor. Todos los días — en este momento mientras estamos hablando — los glóbulos blancos de Mateo están pasando por el riñón trasplantado y viendo esos HLA. Y los ven como extraños. No porque el sistema inmune de Mateo sea defectuoso — sino porque lo son. Son los HLA de otra persona. El sistema inmune de Mateo está diseñado para identificar exactamente eso.”
(The cells of Alejandro’s kidney — Mateo’s father — have identity markers on their surface. They are called HLA, for their acronym in English. They are like a cellular fingerprint: each person has their own. Alejandro’s kidney has Alejandro’s HLA. Mateo’s immune system has Mateo’s HLA — which are similar but not identical to his father’s, because he inherited half from each parent. Every day — right now while we are talking — Mateo’s white blood cells are passing through the transplanted kidney and seeing those HLA proteins. And they see them as foreign. Not because Mateo’s immune system is defective — but because they are foreign. They are someone else’s HLA. Mateo’s immune system is designed to identify exactly that.)
Mateo looks up from his phone. “¿El riñón de mi papá le parece extraño a mi cuerpo?”
(My dad’s kidney seems foreign to my body?)
“Sí. Siempre le ha parecido extraño y siempre le va a parecer extraño. No cambia con el tiempo. Ahora — lo que hace el tacrolimus es bloquear la señal que activa a los glóbulos blancos para atacar cuando ven algo extraño. Esa señal se llama IL-2 — interleucina-2. Los glóbulos blancos de Mateo ven el riñón, lo identifican como extraño, empiezan el proceso de activación, y el tacrolimus bloquea el paso siguiente que los activaría para atacar. Es como si hubiera un freno de mano puesto. Los glóbulos blancos reconocen el riñón pero no pueden actuar.”
(Yes. It has always seemed foreign and it will always seem foreign. It does not change over time. Now — what tacrolimus does is block the signal that activates white blood cells to attack when they see something foreign. That signal is called IL-2 — interleukin-2. Mateo’s white blood cells see the kidney, identify it as foreign, begin the activation process, and tacrolimus blocks the next step that would activate them to attack. It is like having the parking brake on. The white blood cells recognize the kidney but cannot act.)
Sofía leans back slightly. “¿Y si se quita el freno?”
(And if the brake is released?)
“El rechazo empieza. No inmediatamente en el sentido de que Mateo caería enfermo hoy mismo — pero el proceso de rechazo celular agudo comienza en días a semanas después de suspender el tacrolimus. Los glóbulos blancos atacan las células tubulares del riñón, los vasos sanguíneos del riñón. El riñón empieza a dañarse. La creatinina sube. Si no se trata rápidamente, la función del riñón puede perderse permanentemente. Dos años sin rechazo es la prueba de que el tacrolimus está funcionando. No es la prueba de que ya no es necesario.”
(Rejection begins. Not immediately in the sense that Mateo would fall ill today — but the acute cellular rejection process begins within days to weeks after stopping tacrolimus. The white blood cells attack the tubular cells of the kidney, the blood vessels of the kidney. The kidney begins to be damaged. The creatinine rises. If not treated quickly, kidney function can be permanently lost. Two years without rejection is proof that tacrolimus is working. It is not proof that it is no longer needed.)
Sofía is quiet for a moment. “¿Siempre le dije a mis hermanas que quizás en unos años lo podían quitar gradualmente…”
(I always told my sisters that maybe in a few years it could be tapered gradually…)
“Muchas familias tienen esa esperanza — y entiendo por qué. Existen estudios de tolerancia operacional en trasplante renal en adultos — casos documentados donde pacientes seleccionados pudieron reducir y en algunos casos suspender inmunosupresión bajo seguimiento muy estricto. Es un área de investigación activa. Pero no es el estándar de cuidado para Mateo en este momento, y no es algo que yo le podría recomendar. Lo que sí es ciert o es que seguiremos ajustando su dosis para que sea la menor que mantiene el riñón protegido — no más de lo necesario. El objetivo no es tener la dosis más alta, sino la dosis correcta. Por eso medimos el nivel en cada visita.”
(Many families have that hope — and I understand why. There are studies of operational tolerance in adult kidney transplantation — documented cases where selected patients were able to reduce and in some cases stop immunosuppression under very strict monitoring. It is an active area of research. But it is not the standard of care for Mateo at this time, and it is not something I could recommend. What is certain is that we will continue adjusting his dose to the lowest that keeps the kidney protected — not more than necessary. The goal is not to have the highest dose, but the correct dose. That is why we measure the level at every visit.)
Mateo has been listening from across the table. “Entonces el tacrolimus está trabajando aunque yo no lo siento.”
(So the tacrolimus is working even though I do not feel it.)
“Exacto. Que no lo sientas es exactamente el resultado que queremos. El rechazo que el tacrolimus está previniendo — ese sí lo sentirías. Fatiga, creatinina subiendo, el riñón dañándose. El medicamento funciona porque no hay nada que sentir.”
(Exactly. That you do not feel it is exactly the result we want. The rejection that tacrolimus is preventing — that you would feel. Fatigue, creatinine rising, the kidney being damaged. The medication works because there is nothing to feel.)
Sofía folds her paper. The frame she arrived with — the immune system learning, the transplant becoming its own, the medication eventually no longer needed — has been replaced by a different frame: the immune system continuously recognizing, the medication continuously suppressing, the stability as evidence of the medication’s success rather than its obsolescence. She does not look relieved exactly. She looks like someone who has received accurate information and is updating her understanding of what the next decade of her son’s life looks like.
“¿Toda la vida?” she asks quietly.
(His whole life?)
“Mientras tenga el riñón de su papá, sí. Y el riñón de su papá le puede durar muchas décadas si lo cuidamos bien. Es trabajo a largo plazo — para Mateo, para ustedes, y para nosotros.”
(As long as he has his father’s kidney, yes. And his father’s kidney can last many decades if we care for it well. It is long-term work — for Mateo, for you, and for us.)
Scenario 2: Lucía Morales-Fuentes — San Antonio, Texas
Pediatric transplant follow-up nurse Carmen Vargas-Cruz and the parents who cannot understand why their daughter’s tacrolimus dose was increased when her level was in range six months ago
Lucía is eight years old. She received a deceased-donor liver transplant at age three for end-stage biliary atresia following a failed Kasai portoenterostomy. The transplant course was initially complicated by biliary stricture requiring endoscopic dilation at six months, which resolved without recurrence. Since then, she has had stable liver function tests, no acute rejection episodes, and no opportunistic infections. She attends second grade and her parents describe her as indistinguishable from any other eight-year-old except for the twice-daily tacrolimus and the every-three-month clinic visits.
Her parents — Rosa Morales-Herrera, a high school secretary, and Diego Fuentes-Torres, a logistics coordinator for a freight company — arrived at today’s appointment having received a message from the transplant coordinator three days earlier indicating that the morning trough tacrolimus level drawn at the last visit was 3.1 ng per mL and that the physician was recommending an increase from 2 mg twice daily to 3 mg twice daily. Rosa arrived with two questions already formulated: why is the level low when nothing changed, and why is the chart from six months ago showing a level of 8.4 ng per mL on the same dose?
Nurse Carmen Vargas-Cruz sits down with Lucía’s chart open in front of her. She can see the trajectory: levels of 9.2, 8.7, 8.1, 7.3, 5.6, 3.1 over six sequential trough measurements on the same dose over eighteen months. A clear and predictable decline. She knows exactly what is driving it.
“Tienen razón en que el nivel de hace seis meses estaba dentro del rango y la dosis era la misma. Y tienen razón en que Lucía ha estado tomando el medicamento consistentemente — no hay razón para pensar que hubo un problema de adherencia. Entonces la pregunta es válida: ¿por qué bajó el nivel sin que cambiara nada?”
(You are right that the level from six months ago was within range and the dose was the same. And you are right that Lucia has been taking the medication consistently — there is no reason to think there was an adherence problem. So the question is valid: why did the level drop without anything changing?)
Diego nods. “Exactamente.”
(Exactly.)
“Algo sí cambió. Lo que cambió fue el hígado de Lucía — no el hígado trasplantado, sino la capacidad del hígado para procesar el medicamento. Hay una enzima en el hígado que se llama CYP3A4 que es la principal responsable de metabolizar el tacrolimus. Esa enzima no llega a su nivel adulto de actividad en el nacimiento ni en los años pequeños — va aumentando gradualmente durante la niñez y la adolescencia. A los tres años, el hígado de un niño produce cierta cantidad de esa enzima. A los ocho años, produce más. A los doce, más todavía. Mientras más enzima hay, más rápido se procesa el tacrolimus.”
(Something did change. What changed was Lucia’s liver — not the transplanted liver, but the liver’s capacity to process the medication. There is an enzyme in the liver called CYP3A4 that is the main enzyme responsible for metabolizing tacrolimus. That enzyme does not reach its adult level of activity at birth or in early childhood — it increases gradually during childhood and adolescence. At age three, a child’s liver produces a certain amount of that enzyme. At age eight, it produces more. At age twelve, even more. The more enzyme there is, the faster tacrolimus is processed.)
Rosa leans forward. “¿Pero la dosis se calcula por el peso, no? Y Lucía ha crecido.”
(But the dose is calculated by weight, right? And Lucia has grown.)
“Sí, el peso es parte del cálculo. Pero el crecimiento de la enzima no es proporcional al crecimiento del cuerpo. Una niña de 30 kilos a los ocho años no tiene simplemente más hígado que cuando pesó 20 kilos a los cinco años — tiene un hígado con más actividad enzimática por gramo de tejido hepático, porque la maduración de CYP3A4 es un proceso independiente del crecimiento del tamaño. La dosis ajustada por peso asume que si el peso sube un 10%, la necesidad de medicamento sube un 10%. La maduración de CYP3A4 no funciona así. Por eso medimos el nivel directamente — porque es la única manera de saber qué está pasando realmente en el cuerpo de Lucía.”
(Yes, weight is part of the calculation. But enzyme growth is not proportional to body growth. An eight-year-old girl of 30 kilograms does not simply have more liver than when she weighed 20 kilograms at age five — she has a liver with more enzyme activity per gram of hepatic tissue, because CYP3A4 maturation is a process independent of size growth. Weight-adjusted dosing assumes that if weight increases by 10%, medication need increases by 10%. CYP3A4 maturation does not work that way. That is why we measure the level directly — because it is the only way to know what is actually happening in Lucia’s body.)
Diego picks up his phone to show Carmen the chart message he received. “Pero en mayo — aquí dice que el nivel era 8.4. Seis meses después está en 3.1 con la misma dosis. ¿No es un cambio demasiado grande?”
(But in May — here it says the level was 8.4. Six months later it is at 3.1 with the same dose. Is that not too big a change?)
“Es un cambio significativo, y entiendo que preocupa. Cuando miramos la historia de los niveles de Lucía desde los tres años en adelante, vemos exactamente este patrón: los niveles han ido bajando gradualmente en cada medición con la misma dosis ajustada por peso. Era predecible que iba a pasar — por eso hacemos los niveles cada tres meses, para detectarlo antes de que llegue a un nivel en que el sistema inmune empiece a actuar. El nivel de 3.1 está por debajo del rango que el equipo de trasplante considera seguro para Lucía. No hay evidencia de rechazo agudo en este momento — sus enzimas hepáticas están estables. Pero un nivel bajo mantenido produce daño silencioso en el tejido del hígado — inflamación subclínica que no produce síntomas ni cambios notables en el laboratorio hasta que el daño ya tiene meses de acumulación.”
(It is a significant change, and I understand why it is concerning. When we look at the history of Lucia’s levels from age three onward, we see exactly this pattern: the levels have been gradually declining at each measurement on the same weight-adjusted dose. It was predictable that this would happen — that is why we do levels every three months, to detect it before it reaches a level where the immune system begins to act. The 3.1 level is below the range that the transplant team considers safe for Lucia. There is no evidence of acute rejection at this time — her liver enzymes are stable. But a sustained low level produces silent damage in the liver tissue — subclinical inflammation that produces no symptoms and no notable laboratory changes until the damage has been accumulating for months.)
Rosa looks at her daughter, who is drawing on the paper on the exam table. “¿Y si no hubiéramos medido?”
(And if we had not measured?)
“Exactamente. Si no hubiéramos medido, no sabríamos que el nivel está bajo. Lucía se siente bien. Sus enzimas están estables por ahora. Sin la medición del nivel de tacrolimus, seguiríamos con la misma dosis durante meses más, y el daño subclínico seguiría acumulándose. Por eso las visitas de seguimiento incluyen el nivel — no para confirmar que todo está bien, sino para detectar los cambios predecibles antes de que produzcan daño visible. El aumento de dosis que estamos recomendando es la prevención, no el tratamiento de un problema ya establecido.”
(Exactly. If we had not measured, we would not know the level is low. Lucia feels well. Her enzymes are stable for now. Without the tacrolimus level measurement, we would have continued with the same dose for months more, and the subclinical damage would keep accumulating. That is why follow-up visits include the level — not to confirm everything is well, but to detect the predictable changes before they produce visible damage. The dose increase we are recommending is the prevention, not the treatment of an already established problem.)
Diego nods slowly. “¿Y esto va a seguir pasando? ¿La dosis va a seguir subiendo?”
(And will this keep happening? Will the dose keep going up?)
“Hasta que la maduración de CYP3A4 se estabilice — que ocurre generalmente en la adolescencia media, alrededor de los 14 a 16 años. Después de eso, la actividad enzimática se estabiliza y los ajustes de dosis son menos frecuentes. Durante los años de Lucía hasta llegar a la adolescencia, vamos a seguir midiendo y ajustando. Cada ajuste es el sistema funcionando correctamente — no una señal de que algo salió mal.”
(Until CYP3A4 maturation stabilizes — which generally occurs in mid-adolescence, around ages 14 to 16. After that, enzyme activity stabilizes and dose adjustments are less frequent. During Lucia’s years until she reaches adolescence, we will continue measuring and adjusting. Each adjustment is the system working correctly — not a signal that something went wrong.)
Lucía looks up from her drawing. “¿Me van a cambiar la pastilla?”
(Are they going to change my pill?)
“Sí. En vez de tomar dos pastillas de un miligramo dos veces al día, vas a tomar una pastilla de un miligramo y una pastilla de medio miligramo, dos veces al día. El mismo momento, la misma hora, con las mismas instrucciones. Solo un poco más.”
(Yes. Instead of taking two 1-milligram pills twice a day, you will take one 1-milligram pill and one 0.5-milligram pill, twice a day. The same time, the same schedule, with the same instructions. Just a little more.)
“¿Más pastillas?”
(More pills?)
“Una más pequeñita, nada más. Y dentro de tres meses medimos de nuevo para ver si el nivel subió al rango correcto.”
(One small extra one, that’s all. And in three months we measure again to see if the level has come up to the correct range.)
Rosa writes the new dose in her phone. Diego watches Lucía go back to her drawing. The anxiety that brought them into the appointment — the inexplicable lab result, the dose change without apparent cause — has resolved into something more workable: a predictable biological trajectory, a monitoring system that detected it on schedule, and a dose adjustment that is the system working as designed.
Scenario 3: Andrés Espinoza-Torres — Dallas, Texas
Pediatric transplant follow-up nurse Elena Fuentes-Vargas and the parents who cannot understand why their son’s PTLD diagnosis means reducing the immunosuppression that has been keeping his transplanted kidney alive for five years
Andrés is fourteen years old. He received a deceased-donor kidney transplant at age nine for end-stage renal disease secondary to CAKUT (congenital anomalies of the kidney and urinary tract) — specifically bilateral renal hypoplasia with early reflux nephropathy. His post-transplant course was stable for five years on tacrolimus, mycophenolate mofetil, and low-dose prednisone, weaned to alternate days at year two and discontinued at year three. His most recent tacrolimus trough was 6.8 ng per mL. His creatinine had been stable at 0.9 to 1.1 mg per deciliter for three years.
Three weeks ago, Andrés presented to his pediatrician with two weeks of fatigue and painless right-side cervical lymphadenopathy — three lymph nodes palpable, the largest approximately 2.5 centimeters. An EBV viral load drawn at the pediatrician’s office returned elevated: 12,400 copies per mL. The transplant team was contacted; CT of the chest, abdomen, and pelvis showed bilateral cervical lymphadenopathy and mediastinal involvement without hepatosplenomegaly. A biopsy of the largest cervical node returned two days ago: post-transplant lymphoproliferative disorder, EBV-positive, polymorphic type. The attending discussed the results with the family and recommended beginning immunosuppression reduction as primary treatment, with rituximab pending.
Andrés’s parents — Isabel Espinoza-Delgado, who works in hospital billing, and Roberto Torres-Santos, an electrician — were present for the attending visit and heard the recommendation. Roberto left that visit with one question that he could not articulate clearly to the attending but that has been consuming him for three days: “If the immunosuppression is causing the lymphoma, then removing it is the right thing to do for the lymphoma. But the immunosuppression is also the reason the kidney is alive. If you reduce it, doesn’t the kidney reject? How is that a plan?”
Nurse Elena Fuentes-Vargas is doing the education visit before the first reduced-dose tacrolimus is dispensed. She knows from the transplant coordinator that Roberto has been calling with questions since the attending visit, and that Isabel has been searching PTLD online in both Spanish and English and has found articles describing it as a type of lymphoma. She enters the room knowing that this is one of the most difficult conversations in transplant follow-up care — one where the treatment genuinely does involve increasing a real risk in order to address a more acute risk, and where any attempt to minimize that trade-off will fail the family.
“Quiero empezar reconociendo que lo que les explicaron la semana pasada es complicado — y no es que no entendieron bien. Es que la situación en sí misma es complicada. Así que quiero explicar la biología del PTLD desde el principio, porque creo que eso va a hacer que el plan tenga más sentido.”
(I want to start by acknowledging that what they explained to you last week is complicated — and it is not that you did not understand correctly. It is that the situation itself is complicated. So I want to explain the biology of PTLD from the beginning, because I believe that will make the plan make more sense.)
Roberto crosses his arms. “Empiece por el principio.”
(Start from the beginning.)
“El PTLD — el linfoma que encontraron en los ganglios de Andrés — no es un linfoma que llegó al cuerpo de Andrés desde afuera y coincidentemente ocurrió durante el trasplante. Es una enfermedad que existe específicamente porque Andrés está en inmunosupresión. Explicarle eso va a requerir entender qué hace el virus de Epstein-Barr — el EBV — en el cuerpo de una persona con sistema inmune normal, y qué hace diferente en el cuerpo de Andrés.”
(PTLD — the lymphoma found in Andrés’s lymph nodes — is not a lymphoma that arrived in Andrés’s body from outside and coincidentally occurred during the transplant. It is a disease that exists specifically because Andrés is on immunosuppression. Explaining that to you will require understanding what the Epstein-Barr virus — EBV — does in the body of a person with a normal immune system, and what it does differently in Andrés’s body.)
Isabel has her notebook open. “Siga.”
(Go ahead.)
“El EBV es un virus que la mayoría de las personas adquieren durante la niñez o la adolescencia. Una vez que entra al cuerpo, se instala en las células B — un tipo de glóbulo blanco — y establece lo que llamamos latencia: el virus está ahí, en esas células B, para siempre. No desaparece. En una persona con sistema inmune normal, eso no produce enfermedad porque hay otro tipo de glóbulo blanco — los linfocitos T citotóxicos, las células CD8 — que vigilan continuamente las células B infectadas por EBV, las identifican por sus marcadores de EBV en la superficie, y las eliminan si proliferan demasiado. Es una vigilancia activa, continua, todos los días del año.”
(EBV is a virus that most people acquire during childhood or adolescence. Once it enters the body, it settles into B-cells — a type of white blood cell — and establishes what we call latency: the virus is there, in those B-cells, forever. It does not disappear. In a person with a normal immune system, that does not produce disease because there is another type of white blood cell — cytotoxic T-lymphocytes, the CD8 cells — that continuously surveille EBV-infected B-cells, identify them by their EBV surface markers, and eliminate them if they proliferate too much. It is an active, continuous surveillance, every day of the year.)
Roberto unfolds his arms slightly. “¿Y el tacrolimus?”
(And tacrolimus?)
“El tacrolimus suprime los linfocitos T. Esa es exactamente su función — para eso se lo damos a Andrés: para suprimir los linfocitos T que atacarían el riñón trasplantado. Pero los mismos linfocitos T que atacarían el riñón — son los mismos linfocitos T que vigilan las células B infectadas por EBV. El tacrolimus no puede suprimir solo los linfocitos T que atacan el riñón y dejar intactos los que vigilan el EBV. Suprime los dos. Mientras el tacrolimus está funcionando, el riñón está protegido y las células B infectadas por EBV están sin vigilancia. En la mayoría de los pacientes trasplantados, las células B con EBV no proliferan hasta un nivel que cause problema. En Andrés, por razones que incluyen la carga viral de EBV y posiblemente factores de su propia biología inmunológica, proliferaron hasta producir el PTLD.”
(Tacrolimus suppresses T-lymphocytes. That is exactly its function — that is why we give it to Andrés: to suppress the T-lymphocytes that would attack the transplanted kidney. But the same T-lymphocytes that would attack the kidney — are the same T-lymphocytes that surveille EBV-infected B-cells. Tacrolimus cannot suppress only the T-lymphocytes that attack the kidney and leave intact the ones that surveille EBV. It suppresses both. While tacrolimus is working, the kidney is protected and the EBV-infected B-cells are unsupervised. In most transplant patients, EBV-infected B-cells do not proliferate to a level that causes a problem. In Andrés, for reasons that include the EBV viral load and possibly factors of his own immunological biology, they proliferated to produce PTLD.)
Isabel puts down her pen. “Entonces el PTLD existe porque el tacrolimus suprimió las células que debían vigilar el EBV.”
(So PTLD exists because tacrolimus suppressed the cells that were supposed to surveille the EBV.)
“Exactamente. Y eso explica el tratamiento. El tratamiento principal del PTLD — en la fase en que está Andrés, PTLD polimórfico sin transformación a linfoma difuso de células B grandes — es reducir la inmunosupresión. No porque olvidamos que el tacrolimus protege el riñón. Sino porque la única manera de controlar el PTLD sin quimioterapia inicial es restaurar la vigilancia de las células T sobre las células B infectadas por EBV. La inmunosupresión reducida permite que las células T de Andrés empiecen a funcionar lo suficiente como para reconocer y atacar las células B con EBV que están proliferando. En muchos pacientes con PTLD polimórfico, esto es suficiente para inducir regresión completa.”
(Exactly. And that explains the treatment. The primary treatment of PTLD — at the stage Andrés is in, polymorphic PTLD without transformation to diffuse large B-cell lymphoma — is to reduce immunosuppression. Not because we forgot that tacrolimus protects the kidney. But because the only way to control PTLD without initial chemotherapy is to restore T-cell surveillance over EBV-infected B-cells. Reduced immunosuppression allows Andrés’s T-cells to begin functioning enough to recognize and attack the EBV-infected B-cells that are proliferating. In many patients with polymorphic PTLD, this is sufficient to induce complete regression.)
Roberto leans forward. “¿Y el riñón?”
(And the kidney?)
“El riesgo de rechazo aumenta cuando reducimos la inmunosupresión. No voy a decirle que no. Lo que le puedo decir es que vamos a monitorear la función del riñón con más frecuencia de lo habitual — creatinina y proteína en orina cada semana en lugar de cada tres meses. Si el rechazo empieza, lo vamos a detectar antes de que haya daño irreversible. El rechazo agudo en un riñón trasplantado que se detecta temprano frecuentemente responde al tratamiento. El PTLD que no se trata puede progresar a un linfoma sistémico que amenaza la vida de Andrés de una manera que el rechazo no amenaza. El cálculo del equipo es que el riesgo de PTLD progresivo sin tratamiento es mayor que el riesgo de un rechazo manejable con monitoreo intenso. Eso no significa que el riñón no importa. Significa que estamos manejando los dos riesgos al mismo tiempo.”
(Rejection risk increases when we reduce immunosuppression. I am not going to tell you otherwise. What I can tell you is that we are going to monitor kidney function more frequently than usual — creatinine and urine protein every week instead of every three months. If rejection begins, we will detect it before there is irreversible damage. Acute rejection in a transplanted kidney that is detected early frequently responds to treatment. PTLD left untreated can progress to a systemic lymphoma that threatens Andrés’s life in a way that rejection does not threaten. The team’s calculation is that the risk of progressive untreated PTLD is greater than the risk of a manageable rejection with intensive monitoring. That does not mean the kidney does not matter. It means we are managing both risks at the same time.)
Andrés, who has been listening from the exam table, speaks for the first time in the visit. “¿Van a poder salvar el riñón?”
(Are they going to be able to save the kidney?)
Elena looks at him directly. “Eso es lo que estamos tratando de hacer — salvar el riñón y tratar el PTLD al mismo tiempo. No puedo prometerte que el riñón no va a tener ningún efecto del cambio. Lo que sí te puedo prometer es que lo vamos a monitorear lo suficientemente de cerca para actuar si algo cambia. Y lo que los estudios muestran es que la mayoría de los PTLD polimórficos en pacientes trasplantados de niños responden a la reducción de inmunosupresión — muchos con regresión completa. Eso es lo que estamos buscando para ti.”
(That is what we are trying to do — save the kidney and treat the PTLD at the same time. I cannot promise you that the kidney will have no effect from the change. What I can promise is that we will monitor it closely enough to act if something changes. And what the studies show is that most polymorphic PTLDs in pediatric transplant patients respond to immunosuppression reduction — many with complete regression. That is what we are looking for for you.)
Roberto sits back. He is not satisfied — there is no version of this conversation that produces satisfaction. But he has the biological logic now. The PTLD is not an independent disease that arrived; it is the consequence of the same suppression that is protecting the kidney. Restoring the suppressed immune function is both the treatment for the PTLD and a risk for the kidney. The team is managing the risk on both sides with intensive monitoring. He is not being asked to accept the kidney dying; he is being asked to accept a period of intensified monitoring where the kidney is at more risk than it was last week, in order to treat a disease that poses a more acute threat to his son’s life.
“¿Cada semana la creatinina?” he asks.
(Every week the creatinine?)
“Cada semana. Y si algo cambia antes de la siguiente semana — si Andrés siente algo diferente, menos orína de lo normal, hinchazón, fatiga nueva — nos llaman ese día, no esperan a la cita.”
(Every week. And if something changes before the next week — if Andrés notices something different, less urine than normal, swelling, new fatigue — you call us that day, do not wait for the appointment.)
Isabel writes this in her notebook. “¿Y el rituximab que mencionaron?”
(And the rituximab they mentioned?)
“Rituximab es un anticuerpo que elimina las células B — incluyendo las células B infectadas por EBV que están proliferando. En la mayoría de los centros de trasplante pediátrico, el protocolo para PTLD polimórfico es reducir inmunosupresión primero y observar respuesta durante dos a cuatro semanas. Si hay regresión, no se añade rituximab. Si el PTLD no responde a la reducción sola, entonces se añade el rituximab como segundo paso. No estamos añadiendo rituximab todavía — estamos en el primer paso. La decisión de añadirlo o no depende de cómo responde Andrés en las próximas semanas.”
(Rituximab is an antibody that eliminates B-cells — including the EBV-infected B-cells that are proliferating. In most pediatric transplant centers, the protocol for polymorphic PTLD is to reduce immunosuppression first and observe response for two to four weeks. If there is regression, rituximab is not added. If PTLD does not respond to reduction alone, then rituximab is added as a second step. We are not adding rituximab yet — we are at the first step. The decision of whether to add it or not depends on how Andrés responds in the coming weeks.)
Andrés looks at his parents. “¿Y la escuela?”
(And school?)
Elena smiles. “Mientras te sientas bien y no tengas fiebre, la escuela sigue. Queremos que tu vida siga siendo tu vida todo lo posible.”
(As long as you feel well and do not have a fever, school continues. We want your life to keep being your life as much as possible.)
What the transplant follow-up nurse makes visible
The three families in these scenarios share a structural challenge that defines much of the work of pediatric solid organ transplant follow-up nursing: they are confronting recommendations that seem to contradict the evidence they can observe. The transplant looks successful, therefore the medication should eventually end. The child looks well and the last chart value was in range, therefore the dose should not change. The medication has been protecting the kidney for five years, therefore the treatment that requires reducing it cannot be the right response to the new diagnosis. In each case, the observable evidence is accurate but incomplete, and the invisible biological reality — the continuous allorecognition, the CYP3A4 maturational trajectory, the EBV-T-cell balance disrupted by immunosuppression — requires the nurse to make it visible in language the family can carry home.
The transplant follow-up nurse is the clinician who explains what the tacrolimus is doing moment to moment in Mateo’s body, not as a post-surgical recovery but as a continuous suppression of a continuous immune process. Who explains why the same dose that produced a therapeutic trough at age six produces a sub-therapeutic trough at age eight, in language that makes CYP3A4 maturation concrete enough to understand without a biochemistry background. Who explains the PTLD-immunosuppression paradox by tracing the biology of EBV surveillance from first principles — the same T-cells, the same suppression, the same trade-off — so that the treatment plan becomes logically coherent rather than appearing to trade one catastrophe for another.
Transplant medicine asks patients and families to manage invisible risks across decades. The nurse education visits in the transplant follow-up clinic are how families learn to participate in that management intelligently — not by trusting that the medication is correct, but by understanding why it is correct, and what to do when the situation changes.
Internal links for further reading
For related pediatric specialty conversations involving ongoing immunosuppression and immune system management: Spanish for pediatric immunodeficiency clinic nurses covers the conversations with Spanish-speaking families about the immune system deficits that require lifelong replacement or prophylaxis — XLA, SCID, CGD — providing the immunological vocabulary that is foundational to the transplant immunology discussions in this post, particularly around B-cell and T-cell function. Spanish for bone marrow transplant nurses covers a different but related transplant context — hematopoietic stem cell transplantation for hematological malignancy — with overlapping communication challenges around immunosuppression duration, infection risk, and graft-versus-host disease that share structural similarities with the solid organ transplant communication challenges in this post. Spanish for kidney transplant rejection clinic nurses covers acute and chronic rejection conversations for adult and adolescent kidney transplant patients, including the creatinine monitoring, biopsy discussions, and rejection treatment conversations that are closely related to the rejection risk management discussions in the Andrés scenario. Spanish for pediatric oncology clinic nurses covers the cancer diagnosis and treatment discussions that overlap with the PTLD discussions in this post, including the conversations about lymphoma diagnosis, staging, and treatment options for families navigating a cancer diagnosis in a child who also has a complex medical background. For the vocabulary foundation underlying all of these conversations, the 50 essential clinical Spanish phrases PDF covers the intake, assessment, and explanation phrases used in every specialty encounter. Browse the full ClinicaLingo blog for the complete library of pediatric and adult specialty conversations, or practice the communication skills with interactive scenario practice.